INTRODUCTION
Hepatitis C virus (HCV) infection in Egypt represents a massive challenge facing the country with high prevalence rates within the Egyptian population of different age groups. Genotype 4 (GT4) is the most prevalent genotype in Egypt. It is estimated that 10% of the Egyptian population between 15 and 59 years of age are chronically infected with HCV. Moreover, the rate of infection keeps on with age. This means 8-10 million people are living with viral hepatitis with millions more at risk of infection [1].
Since the production of the first directacting antiviral (DAA) agent, great advances have been witnessed in the field of chronic HCV treatment.
Sofosbuvir (an NS5B polymerase inhibitor) is the milestone in almost all of the DAA-based therapeutic regimens. It is a nucleotide analogue that inhibits viral RNA synthesis. Approved by the FDA in 2013 [2], Sofosbuvir (SOF) has shifted the field of chronic HCV treatment into another direction through introducing all-oral regimes that are based on using a combination of 2 or more DAAs, providing the following advantages:  Pangenotypic activity against all known virus genotypes.  Higher efficacy compared to the previous interferon (IFN)-based treatment regimens (SVR12 rates >90%).  Shorter duration of therapy (as short as 8 weeks).
 Fewer adverse effects.  Possibility of once daily administration that improved adherence of patients and reduced cases of treatment discontinuation.
Daclatasvir (DCV) is an NS5A inhibitor that exerts its action through two mechanisms. The first is blocking HCV RNA synthesis. The second involves inhibiting viral assembly and release. Approved by the FDA in 2015, DCV has been added to SOF as a combination to treat chronic HCV infection [3] .
The aim of this study was to evaluate the efficacy of a protocol composed of (SOF+DCV±RBV) in treating naïve Egyptian patients, either cirrhotic or non-cirrhotic, in Sharkia governorate, Egypt.
PATIENTS AND METHODS
This prospective cohort study was conducted in Tropical Medicine Department, Zagazig University Hospitals, Egypt in the period between March 2017 and February 2018. A total of one hundred patients participated in the study.
Inclusion criteria:
All participants were treatment-naïve Egyptian patients infected with chronic HCV, evidenced by +ve HCV RNA quantitative PCR results with at least twice elevations of liver enzymes in the preceding 6 months. In addition patients without and with compensated cirrhosis were included. Diagnosis of cirrhosis was carried out by means of combined imaging, clinical, and laboratory data. SOF and DCV were administered at a dose of 400mg q.d orally and 60mg q.d orally respectively. For those who received RBV, 600 mg were administered daily orally.
The following were carried out for all participants:  Recording full history. 
Follow up:
Patients were followed up throughout the course of treatment by clinical evaluation, CBC, liver function tests, and kidney function test after one week and two weeks of treatment, then every month till the end of treatment (EOT). PCR for HCV RNA was performed 4 weeks after initiation of therapy, End of Treatment (EOT), and 3 months after cessation of therapy (SVR12).
End points:
The percentage of patients in each treatment group achieving sustained virological response (SVR12) was considered the primary efficacy end point. SVR12 was defined as HCV RNA less than 15 IU/mL when measured twelve weeks after cessation of therapy [5].
Statistical analysis:
Statistical analysis of collected data was carried out using IBM ® SPSS program, version 20.
Differences between qualitative variables were examined via Chi square test (χ2). On the other hand, expression of quantitative data was in terms of mean ± SD (Standard Deviation) for parametric data, while mean and range were used for non-parametric data.
Parametric variables among the three groups were compared via independent samples t-test. In addition, changes before and after the course of treatment for parametric variables were compared using paired samples t-test. Quantitative data at different time intervals were compared using one way ANOVA test. Significance Level was defined at P-value ≤ 0.05 [8].
RESULTS

Study population:
This study included 100 patients from Sharkia governorate, Egypt with chronic HCV GT4 infection. Patients' age ranged from 27 to 72 years old. Out of the 80 patients in the treatment groups, male represented 40% (32), while female represented 60% (48). 48 patients (60%) were non-cirrhotic and 32 (40%) patients were cirrhotic. All cirrhotic patients were Child A.
No statistically significant difference in demographic data was present at baseline among the three groups included in the study as (Table 1) shows.
Patients in this study were treated according to the latest Egyptian guidelines of the NCCVH [4], which are in accordance with the latest guidelines issued by the WHO [9].
Virological response:
Results of this study show with no doubt the high efficacy of the protocol composed of DCV+SOF for a duration of 12 weeks with or without the addition of RBV in treatment of both noncirrhotic and cirrhotic patients. This is highly evident by the SVR12 rates achieved in both groups that received treatment, where 100% of patients in both dual and triple therapy groups achieved SVR12. Moreover, the results of PCR tests were negative 4 weeks after initiation of therapy, and continued to be negative at EOT, and 3 months after EOT (SVR12) ( Table 2 ).
Biochemical and clinical parameters:
It seems that biochemical and clinical parameters could benefit from such combination. Statistically significant differences in almost all measured parameters were observed in the data pretreatment and at EOT as shown in (Table3).
Furthermore, statistically significant differences in these parameters were observed since the beginning of treatment and were apparent in the data collected throughout the course of treatment, though not shown here. Note that (-) sign indicates the increase in the mean of a measured parameter at the end of treatment. Following its approval for use in treatment of HCV infection, the high efficacy it achieved along with being known for its pangenotypic activity, has gained SOF the approval to be used in treatment of GT4 infection in Egyptian patients.
DISCUSSION
Moreover, Egypt was licensed to manufacture certain generic products of the potent DAA, including sofosbuvir and daclatasvir, making them available at affordable prices [11] .
In November 2015, the NCCVH protocol was updated and new regimens were added including SOF+DCV±RBV among other regimens [4].
Since it is the currently applied regimen and since previous studies have recommended further studies with close monitoring and thorough follow up of patients in attempt to assess the efficacy profile of DCV+SOF regimen with or without RBV, SOF+DCV+RBV regimen was the focus of this study. It is worth noting that SVR12 rate reported in this study, giving that Egyptian patients are predominantly infected with GT4, is higher than that reported for patients infected with other genotypes and treated with the same protocol, where in a study of Sulkowski et al. [18] , the SVR12 rates achieved were 98%, 92%, and 89% in GT1, GT2, and GT3 patients respectively. It is worth noting that the highest rates were achieved in GT1a and GT1b patients who showed 98% and 100% SVR12 rates respectively.
On the other hand, Nelson et al. [19] reported SVR12 rate of 90% in 101 GT3-infected patients who were treatment-naïve and received treatment with a combination of DCV+SOF for a duration of 12 weeks. Compared to the findings of this study, it seems that the treatment protocol possesses higher potency in treatment of GT 4 infected patients.
Finally, not only is sofosbuvir + daclatasvir + ribavirn regimen highly potent when it comes to our cohort of GT 4-infected Egyptian patients, as evidenced by the 100% SVR rate, but also it led to improvements in the clinical items and biochemical parameters by the end of therapy.
Moreover, in addition to its high efficacy, being able to produce sofosbuvir and daclatasvir locally means their affordability, which is largely in favor of this combination and a very important factor to consider. Most likely the combination of SOF + DCV will still be present in the Egyptian market and used in treatment of Egyptian patients in the foreseeable future.
In conclusion, the combination of Daclatasvir and Sofosbuvir with or without ribavirin administered for a duration of 12 weeks is highly effective in treatment-naïve Egyptian patients with or without cirrhosis achieving SVR rates of 100%.
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